53 results about "Bladder cancer cell" patented technology

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.

This invention discloses a chimeric guide RNA integrating RNA interference and CRISPR-Cas13d and its applications. Utilizing the structural matching between shRNA and Cas13d crRNA, this invention embeds the complete Cas13d crRNA into the classic shRNA backbone, constructing a dual-pathway synergistic silencing chimeric guide RNA (SS-Rx). Experiments have demonstrated that SS-Rx possesses the dual activity of shRNA and CRISPR-Cas13d, exhibiting superior gene silencing efficiency compared to traditional RNA silencing tools, and can inhibit the proliferation, migration, and invasion of bladder cancer cells by suppressing tumor-related genes. This invention synergistically combines the advantages of RNA interference and CRISPR-Cas13d, providing an efficient and widely applicable framework for gene function research and RNA-targeted therapy, with significant economic benefits and broad application prospects.

The present invention relates to: a pharmaceutical composition comprising at least 99% of tetraarsenic hexoxide crystalline polymorph a(As4O6-a) for preventing or treating bladder cancer; or a preparation method therefor. The composition of the present invention exhibits an excellent effect of inhibiting the proliferation and metastasis of bladder cancer cells, and thus can be effectively used as an anticancer agent for bladder cancer.

The invention discloses a staurosporine glucoside derivative as well as a preparation method and application thereof, and belongs to the field of medicine synthesis. C3-NHCH3 of staurosporine is subjected to glycosylation modification, and the staurosporine glycoside derivative shown in the formula (I) is prepared. The glycoside derivative prepared by the invention has a better inhibition effect on human acute myeloid leukemia cells THP-1, human bladder cancer cells 5637, human colon cancer cells HCT-116, human pancreatic cancer cells PATU8988T and human liver cancer cells HuH-7, and the compound 5 also has an excellent inhibition effect on human gastric cancer cells MKN-45. A candidate compound is provided for development of drugs for bladder cancer, colon cancer, pancreatic cancer, liver cancer, stomach cancer or acute myeloid leukemia.

The application provides a chiral 2-position disubstituted indoline compound and a synthesis method and application thereof. The application uses a simple structure palladium catalyst and a chiral ligand as a catalyst system, and uses a newly designed allyl benzoxazinone as a raw material to perform a palladium catalyzed intramolecular asymmetric cyclization reaction, so that efficient asymmetric synthesis of the chiral 2-position disubstituted indoline compound is realized. The synthesis method is simple, the reaction condition is mild, the cost is low, and the efficiency is high; the raw material is cheap and easy to obtain, atom economy is good, and the substrate is widely applicable; the target product has high yield and high enantioselectivity; the chiral 2-position disubstituted indoline compound obtained by the application has excellent inhibition effect on bladder cancer cells, provides a scientific basis for developing a new candidate drug for treating bladder cancer, and has important significance for the treatment of bladder cancer.

The present application belongs to the field of biotechnology, and particularly relates to a new target for bladder cancer proliferation and metastasis progression research and application thereof, more particularly to LAMP5 as a marker for bladder cancer diagnosis and prognosis, and application of LAMP5 as a bladder cancer marker in preparation of a molecular targeted drug. The present application constructs a stable cell strain with LAMP5 expression knocked down in J82 and T24T cell strains, and functional experiments show that inhibition of LAMP5 expression can inhibit the proliferation and metastasis of bladder cancer cells in vitro and ectopic tumor in vivo. It can be seen that LAMP5 expression can be inhibited by using an LAMP5 expression inhibitor, thereby providing a potential therapeutic target for bladder cancer treatment.

The present invention provides a pyrazolo[1,5-a]pyrimidine-7-oxide compound, a preparation method and uses thereof, belonging to the field of chemical drugs. The structure of the pyrazolo[1,5-a]pyrimidine-7-oxide compound is shown in Formula I. Experimental results show that such compounds can effectively inhibit the growth of various tumor cells including lung cancer cells, breast cancer cells, prostate cancer cells, bladder cancer cells, and esophageal cancer cells, and have broad application prospects in the preparation of drugs for preventing and / or treating tumors.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

The invention belongs to the technical field of biological medicines, and discloses a preparation method of a rhizoma smilacis glabrae exosome and application of the rhizoma smilacis glabrae exosome in bladder cancer. The preparation method comprises the following steps: cleaning, soaking and slicing a rhizoma smilacis glabrae medicinal material, adding a phosphate buffer solution, juicing in a juicer, and filtering to obtain crude juice; sequentially carrying out low-speed, medium-speed and ultra-high-speed centrifugal treatment through a differential ultra-speed centrifugal method to obtain a rhizoma smilacis glabrae precipitate; and resuspending by using a phosphate buffer solution, carrying out ultra-high-speed centrifugation and filtering by using a filter membrane to obtain the rhizoma smilacis glabrae exosome. System experiments prove that the exosome-like nano-particles extracted from rhizoma smilacis glabrae can be effectively taken by bladder cancer cells, can significantly inhibit the growth of bladder cancer in vivo and in vitro by inhibiting proliferation and invasion of cancer cells, inducing oxidative stress, apoptosis, cell cycle arrest and other mechanisms, and has no obvious toxic or side effect on normal tissues; good biological safety and clinical application prospects are realized.

The present invention relates to a composition for preventing or treating bladder cancer, in particular, to a composition for preventing or treating cancer, comprising a nucleic acid encoding a proenkephalin (PENK) protein, which is a cancer inhibitory protein that is inhibited by methylation in cancer cells, in particular, a PENK protein that is inhibited by methylation in bladder cancer cells. Thus, the composition inhibits proliferation of bladder cancer cells.

The invention discloses a bladder cancer cell and a method for constructing a mouse bladder cancer in-situ model by using the bladder cancer cell. The preservation number of the bladder cancer cells is CCTCC (China Center For Type Culture Collection) NO: C2025187. The migration and invasion abilities of bladder cancer cells provided by the invention are higher than those of parent cells, when the bladder cancer cells are used for constructing a mouse bladder cancer in-situ model, the tumor growth speed, proliferation ability and modeling rate are higher than those of the parent cells, and an efficient animal model platform is provided for bladder cancer related research.

The application relates to a bladder cancer fine typing method and system based on nucleic acid aptamer differential analysis, which comprises the following steps: incubating a sample containing bladder cancer cells through a probe package, and performing high-throughput gene sequencing on the incubated sample to obtain sequencing data; removing abnormal samples from the sequencing data to obtain nucleic acid aptamer data; standardizing the nucleic acid aptamer data to obtain standard data including a health sample group and a case sample group; selecting differential expression aptamers from the standard data; and typing a to-be-tested sample through the differential expression aptamers. The application can identify the expression difference of specific nucleic acid aptamers in bladder cancer cells, and further realizes fine typing.

The present invention belongs to the field of traditional Chinese medicine biotechnology, and specifically relates to a phenolic compound, its preparation method and application. The phenolic compound is a pair of diastereoisomers, where Formula I is the dextrorotatory form, named (+)-fresh bamboo juice phenol B, and Formula II is the levorotatory form, named (−)-fresh bamboo juice phenol B. The present invention successfully obtained a pair of diastereoisomeric phenolic compounds, (+)-fresh bamboo juice phenol B and (−)-fresh bamboo juice phenol B, from fresh bamboo juice. Through in vitro cell experiments, it was found that both of them have significant inhibitory effects on human gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells, and can be used in the preparation of drugs for preventing or treating tumors, showing broad application prospects.

The application discloses application of NDUFB4 as a target point in preparation of a drug for treating bladder cancer. Single cell analysis results show that NDUFB4 is highly enriched in bladder cancer epithelial cells, and can be used as a key coordinator to participate in the regulation of multiple carcinogenic signal pathways. Through shRNA-mediated gene silencing and CRISPR / Cas9-mediated gene knockout experiments, it is found that NDUFB4 deletion can significantly inhibit the proliferation, migration and invasion ability of bladder cancer cells, and cause a serious bioenergy crisis, and activate the endogenous apoptosis pathway. In a subcutaneous xenotransplant tumor model, it is further verified that NDUFB4 silencing can significantly inhibit tumor growth. The application discloses that NDUFB4 is a key coordinator between mitochondrial high-functionality and carcinogenic signal pathways, and it is suggested that NDUFB4 can become a potential target for bladder cancer treatment.

The invention discloses a new application of rhizoma paridis total saponins in preparation of a medicine for enhancing bladder cancer cell ferroptosis and apoptosis sensitivity, the rhizoma paridis total saponins are combined with a GPX4 inhibitor JKE for use, and experiments show that the rhizoma paridis total saponins can enhance the sensitivity of bladder cancer cells (UM-UC-3, T24CDDP) to the JKE, and cooperate with the JKE to reduce the median inhibitory concentration of the bladder cancer cells, so that the bladder cancer cell ferroptosis and apoptosis sensitivity can be enhanced, and the bladder cancer cell ferroptosis and apoptosis sensitivity can be enhanced. The paris polyphylla total saponins are combined with JKE, the synergistic effect is dose-dependent within a certain range, and in the aspect of ferroptosis, when the paris polyphylla total saponins and JKE are used in a combined manner, C11-BODIPY detection finds that cells can be more effectively induced to generate lipid peroxidation, and ferroptosis is promoted. An apoptosis detection result shows that the rhizoma paridis total saponins can enhance the effect of inducing bladder cancer cell apoptosis by JKE, and flow cytometry detection shows that the apoptosis rate is remarkably increased when the rhizoma paridis total saponins are combined for use; the combined application of the rhizoma paridis total saponins and the JKE provides a new effective strategy for bladder cancer treatment.

The invention provides a sugar nucleic acid dual-targeting radioactive molecular probe for targeted therapy of bladder cancer as well as a preparation method and application of the sugar nucleic acid dual-targeting radioactive molecular probe, and belongs to the technical field of biological medicines. The probe is composed of an Sgc8 aptamer for recognizing bladder cancer cell PTK7 protein, three nitrine mannose molecules of a targeted M2 type macrophage CD206 receptor and a DOTA structure for chelating 177Lu, and precise assembly is achieved through a click chemical reaction and complementary base pairing. The probe has dual targeting ability, can act on bladder cancer cells and M2 type macrophages in a tumor microenvironment at the same time, significantly prolongs the retention time (gt, 48 hours) in the bladder, induces immune activation while killing tumor cells, and realizes the synergistic effect of radiotherapy and immunotherapy. The problems that an existing bladder cancer treatment probe is insufficient in targeting, poor in stability and limited in treatment effect are solved, a new strategy is provided for precise treatment of bladder cancer, and the bladder cancer probe has good clinical transformation value.

The invention provides an application of an HIF-3alpha-3 gene or a protein coded by the HIF-3alpha-3 gene in preparation of a medicine for preventing and treating bladder cancer, and belongs to the technical field of biological medicines. The invention reveals that HIF-3alpha-3 in bladder cancer up-regulates PHD3 gene expression from a transcriptional regulation level, so that the hydroxylation level of HIF-1alpha in bladder cancer cells is increased, and the protein stability of HIF-1alpha is reduced for the first time. Meanwhile, overexpression of the HIF-3alpha-3 gene or the coded protein can effectively inhibit proliferation and in-vivo tumorigenicity of bladder cancer cells. Therefore, the invention provides the application of the HIF-3alpha-3 gene or the protein coded by the HIF-3alpha-3 gene or the PHD3 gene or the protein coded by the PHD3 gene in preparation of medicines for preventing and treating bladder cancer.

The application discloses a kind of 1,5-diaryl-1,2,4-triazole compounds or pharmaceutically acceptable salt represented by structural formula I, II or pharmaceutical composition containing such compounds.The application also discloses the application of the compound or pharmaceutically acceptable salt in the preparation of drugs for treating various malignant tumors and related diseases of tumor metastasis.The compound represented by formula I, II of the application can inhibit the proliferation, invasion and infiltration of tumor cells such as gastric cancer cells, breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells and bladder cancer cells in a concentration gradient-dependent manner, has the characteristics of high efficiency and low toxicity, and has a wide application prospect in the biological medicine industry.

The application discloses a bladder cancer cell segmentation method and device based on urine sediment microscopy and a storage medium; the method comprises the following steps: taking a urine sediment microscopy image as an input image, inputting the input image into a detection model, marking a high-suspected cancer cell area in the input image through the detection model, and generating a boundary box; segmenting the high-suspected cancer cell area in the boundary box through a segmentation model, obtaining a mask of each cancer cell, deleting the corresponding boundary box if the mask is empty or the area ratio is lower than a preset threshold, mapping the effective mask back to the input image, merging all the effective masks, and generating a segmentation result of the cancer cells. The detection model can effectively reduce the processing range of the segmentation model, avoid the waste of computing resources caused by full-image search, and improve the processing speed. The segmentation model can automatically filter out false detection or invalid areas, and ensure the accuracy and reliability of the segmentation result.

The invention discloses a new application of tripterine, namely application of the tripterine in preparation of bladder cancer resisting drugs, in-vitro cell experiments prove that the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP, the median inhibitory concentration (IC50) of the tripterine is 0.2688-0.5870 mu M, and the tripterine shows remarkable proliferation inhibition activity on various bladder cancer cell strains including cell strains UM-UC-3, TCCSUP and T24 and a cis-platinum drug-resistant strain T24CDDP. The further mechanism research shows that the tripterine can regulate and control the cell cycle by down-regulating the expression levels of CDK1 and CDC5L proteins in bladder cancer cells and up-regulating the expression of phosphorylated p53 (p-p53) proteins at the same time, thereby playing a role in resisting bladder cancer; the invention provides a new effective candidate drug for clinical treatment of bladder cancer, especially cis-platinum resistant bladder cancer, and has important clinical application value.

The invention relates to an engineered exosome for targeting bladder cancer cells as well as a preparation method and application of the engineered exosome, and the engineered exosome is specific siRNA (small interfering Ribonucleic Acid) which is subjected to surface modification with concanavalin A and loaded with CASC11, and is marked as ConA-EXO-siCASC11. According to the invention, the engineered exosome is modified by ConA, so that the CASC11-siRNA is effectively delivered to the BLCA cells, the therapeutic effect of the CASC11-siRNA on the BLCA cis-platinum resistance is explored, an emerging therapeutic scheme is provided for the cis-platinum resistance BLCA, and the development of the field of precise treatment based on the engineered exosome is promoted.

The invention discloses an application of cypress hydrolat in preparation of antitumor drugs. The tumors comprise liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and / or bladder cancer. Experiments show that the cypress hydrolat has an obvious inhibition effect on proliferation of gastric cancer SGC-7901, lung cancer A549, cervical cancer Hela, liver cancer Bel-7402 and HepG2, prostatic cancer PC-3 and bladder cancer EJ cells, can inhibit migration of two human liver cancer Bel-7402 and HepG2 cells, can prolong life of ascites tumor mice and inhibit growth of tumors, and can be used for preparing the cypress hydrolat. The cypress hydrolat has antineoplastic activity and antineoplastic effect, has the patent medicine potential of preparing medicine preparations for preventing or treating tumors, and can be used for developing and preparing antineoplastic medicines. The invention provides a new drug source for treating and curing liver cancer, gastric cancer, lung cancer, cervical cancer, prostatic cancer and bladder cancer, and provides a certain experimental basis for clinical application of the cypress hydrolat and development of new antitumor drugs.

The invention relates to a covalent nucleic acid aptamer. The covalent nucleic acid aptamer comprises any one of S2 nucleic acid aptamer DNA sequence as shown in SEQ ID NO: 1, S2 nucleic acid aptamer DNA sequence as shown in SEQ ID NO: 2; the DNA sequence of the S2v1 aptamer is as shown in SEQ ID NO: 2; and the DNA sequence of the S2v2 aptamer is as shown in SEQ ID NO: 3. The aptamer also comprises phosphorothioate modification at the 3'end of the S2v2 and addition of an electrophilic group. In the aptamer, six T basic groups are added at the 3'end of S2v2, and phosphorothioate modification is carried out. Further, the aptamer reacts with 4-(bromomethyl) benzenesulfonyl fluoride to modify an electrophilic group, and the aptamer can form covalent binding with cells. The nucleic acid aptamer has high specificity, high affinity and no immunogenicity, can be chemically synthesized in vitro, can target bladder cancer cells, and is relatively strong in binding capacity. In addition, the aptamer can kill or inhibit bladder cancer cells, the effect is obvious, and targeted therapy of bladder cancer is facilitated.

The invention provides an exosome preparation with a treatment function and a preparation method thereof, and belongs to the technical field of cell biology. The exosome preparation is prepared by subjecting stem cells to first-stage alpinetin stimulation and second-stage low-intensity magnetic field stimulation, and can effectively inhibit bladder cancer cell proliferation and migration and enhance the sensitivity of bladder cancer cells to chemotherapy drug paclitaxel, so that a novel biological treatment strategy is provided for overcoming bladder cancer chemotherapy drug resistance; the important clinical transformation value is realized.

The invention discloses an FGFR3 (Fibroblast Growth Factor Receptor 3) targeting antibody coupling medicine as well as a preparation method and application thereof. The antibody coupling medicine LZU-WZLYCS01 is formed by coupling an FGFR3 (Fibroblast Growth Factor Receptor 3) antibody with a cytotoxic load 7-ethyl-9-fluorocamptothecin through a cleavable linker GGFG (Growth Growth Factor Growth). The antibody coupling medicine disclosed by the invention shows remarkable cell growth inhibition activity on bladder cancer cells (such as T24 and UMUC-3), IC50 values within 72 hours are 0.005 mu M and 0.009 mu M respectively, and the antibody coupling medicine shows accurate targeting capability based on an FGFR3 target spot. In a bladder cancer organ model, a cell line-derived xenotransplantation tumor (CDX) model and a patient-derived xenotransplantation tumor (PDX) model, the LZU-WZLYCS01 can be used for effectively inhibiting tumor growth and has good safety. Therefore, the antibody coupling medicine is a candidate medicine with great potential for targeted therapy of bladder cancer.

This invention discloses the application of TRIM21-related biopharmaceuticals in the preparation of YME1L1-related products. It reveals the interaction between TRIM21 and YME1L1 and its key regulatory mechanism in the development and progression of bladder cancer. Studies show that TRIM21 specifically binds to the YME1L1 protein through its SPRY domain, mediating K63-linked ubiquitination modification of YME1L1 and thus promoting its protein degradation. Functional experiments confirm that TRIM21 inhibits the proliferation, migration, invasion, and mitochondrial function of bladder cancer cells and induces apoptosis by downregulating YME1L1 protein levels. This invention elucidates for the first time the tumor-suppressive mechanism of the TRIM21-YME1L1 signaling axis in bladder cancer, providing a new molecular marker for the diagnosis and prognostic assessment of bladder cancer, and offering a theoretical basis and intervention strategy for developing anti-tumor drugs targeting the TRIM21 / YME1L1 pathway.

The invention relates to a bladder cancer cell inhibitor taking TNKS2 protein as a target as well as a preparation method and application thereof, the bladder cancer cell inhibitor is a 1, 3, 5-triazine compound, the structural formula of the bladder cancer cell inhibitor is shown in the specification, and the preparation method comprises the following steps: taking 2, 4, 6-trichloro-1, 3, 5-triazine as a raw material, under an alkaline condition, dissolving the 2, 4, 6-trichloro-1, 3, 5-triazine in dichloromethane, stirring in an ice bath, filtering, washing, and drying to obtain the bladder cancer cell inhibitor taking TNKS2 protein as a target. Then adding N-(2-aminoethyl) morpholine, continuously stirring to react, and filtering separated solids after the reaction is finished to obtain a compound 1; dissolving the compound 1 and 2-(2-pyridyl) ethylamine in methanol, reacting at room temperature, separating out a white solid, and filtering to obtain a compound 2; the bladder cancer cell inhibitor is obtained by taking tetra (triphenyl) phosphine palladium as a catalyst, enabling a compound 2 to react with a phenylboronic acid derivative under an alkaline condition and in a nitrogen atmosphere, and performing post-treatment after the reaction is finished. Compared with the prior art, the product prepared by the invention has better bladder cancer cell selectivity and inhibitory activity.

The present application relates to a kind of preparation of new indole camptothecin derivatives and its use in antitumor, the structure of the compound general formula is shown as follows.In vitro cytotoxic activity screening results show that new indole camptothecin derivatives have broad-spectrum antitumor activity, to human hepatoma cell (HepG2), human non-small cell lung cancer cell (A549), human colon cancer cell (SW480), human intrahepatic cholangiocarcinoma cell (RBE), human breast cancer cell (MCF-7), human pancreatic cancer cell (BxPC3), human bladder cancer cell (T24), human bladder cancer cell (umuc3) show strong inhibitory activity. Among them, the antitumor activity of compound D-18 is most outstanding, and shows strong inhibition to the 8 tumor cell lines measured, IC 50 The range is 0.2585-10.69 μM, significantly better than the control drug irinotecan, and comparable to topotecan activity. Therefore, indole camptothecin derivatives are expected to be developed into a new antitumor drug.

The invention discloses application of jujuboside A in treatment of bladder cancer. Cell experiments prove that jujuboside A can reduce the activity of bladder cancer cells and induce apoptosis of the bladder cancer cells, and can inhibit expression of ATP1A2 in the bladder cancer cells and mitochondrial energy metabolism. The application provides a brand new thought for research and development of bladder cancer treatment medicines, and has a wide application prospect.

The invention provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, and provides application of amentotaxus biflavone in preparation of a medicine for treating bladder cancer, which has the advantages that by increasing the concentration of amentotaxus biflavone, the number of bladder cancer cells is gradually reduced, the cells are shrunk, nuclear shrinkage of different degrees is caused, the activity, proliferation, invasion and migration of bladder cancer T24 cells and bladder cancer 5637 cells are inhibited, and the bladder cancer is treated. The PI3K / AKT / NF-kappa B pathway promotes the expression of a pro-apoptosis gene Bax in bladder cancer cells, inhibits the expression of an apoptosis inhibitor gene Bcl-2, inhibits the proliferation of the bladder cancer cells by inducing G1 phase retardation of the bladder cancer cells, induces and reduces the expression of PI3K, AKT and NF-kappa B proteins in cell nucleuses through the PI3K / AKT / NF-kappa B pathway, and induces the apoptosis of the bladder cancer cells. The invention belongs to the field of medicine.